315 related articles for article (PubMed ID: 18552874)
21. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
Gupta A; Lawrence AT; Krishnan K; Kavinsky CJ; Trohman RG
Am Heart J; 2007 Jun; 153(6):891-9. PubMed ID: 17540188
[TBL] [Abstract][Full Text] [Related]
22. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
23. Drug-induced prolongation of the QT interval: why the regulatory concern?
Shah RR
Fundam Clin Pharmacol; 2002 Apr; 16(2):119-24. PubMed ID: 12031064
[No Abstract] [Full Text] [Related]
24. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
[TBL] [Abstract][Full Text] [Related]
25. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
Cubeddu LX
Am J Ther; 2003; 10(6):452-7. PubMed ID: 14624285
[TBL] [Abstract][Full Text] [Related]
26. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
27. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
Lin JC; Quasny HA
Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
[TBL] [Abstract][Full Text] [Related]
28. Torsade de pointes induced by ajmaline.
Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
[TBL] [Abstract][Full Text] [Related]
29. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Lu HR; Remeysen P; De Clerck F
J Cardiovasc Pharmacol; 2000 Dec; 36(6):728-36. PubMed ID: 11117372
[TBL] [Abstract][Full Text] [Related]
30. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
31. [Why is QT interval interesting?].
Elming H; Sonne J; Lublin HK
Ugeskr Laeger; 2002 Feb; 164(6):750-4. PubMed ID: 11851179
[TBL] [Abstract][Full Text] [Related]
32. [QTc-prolonging drugs and the risk of sudden death].
Reingardiene D; Vilcinskaite J
Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
[TBL] [Abstract][Full Text] [Related]
33. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
[TBL] [Abstract][Full Text] [Related]
34. Drug induced QT prolongation and torsades de pointes.
Yap YG; Camm AJ
Heart; 2003 Nov; 89(11):1363-72. PubMed ID: 14594906
[No Abstract] [Full Text] [Related]
35. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced QT prolongation and sudden death.
Del Rosario ME; Weachter R; Flaker GC
Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
[TBL] [Abstract][Full Text] [Related]
37. Drug-induced torsades de pointes and implications for drug development.
Fenichel RR; Malik M; Antzelevitch C; Sanguinetti M; Roden DM; Priori SG; Ruskin JN; Lipicky RJ; Cantilena LR;
J Cardiovasc Electrophysiol; 2004 Apr; 15(4):475-95. PubMed ID: 15090000
[TBL] [Abstract][Full Text] [Related]
38. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
39. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
40. Antiarrhythmic drugs and torsade de pointes.
Lazzara R
Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
